PharmExec Blog
Follow Us
RSS
Bookstore
By Jill Wechsler, Washington Correspondent.
The Food and Drug Administration has come down on the side of reducing abuse of opoid medications, over encouraging wider availability of low-cost painkiller meds. The agency decided to block generic versions of the original OxyContin formulation, which is fairly easy to manipulate by illegal users. The aim is to help halt the epidemic of prescription drug abuse raging across the country. FDA’s decision leaves the market open to Purdue Pharma’s newer version of the drug, which the agency determined has features that make it more difficult to abuse via injection or snorting. Read More
Forget Digital Differentiation: Focus on Cross-Channel 'Fusion'
Forget digital differentiation and innovation. You need to be focusing on cross-channel ‘fusion’, writes Peter Houston.
Like you, I get invites to attend educational webinars on an almost daily basis; I probably actually attend one every couple of weeks.
Most invites get passed over because it’s not my field, I’ve heard it all before or I don’t have the time to attend. One caught my eye recently though, mainly because a phrase in the title chimed with a lot of the work I am doing in the magazine market: “Cross-channel”. Read More »